07 · STUDIES, REVIEWS, AND FEDERAL PAGES
BPC-157 TB-500 references: what does each kind of source answer?
Human reviews show the safety gaps. Animal papers report tendon and wound changes. FDA pages explain approval and pharmacy access.
Which sources answer safety, healing, and pharmacy questions?
The human reviews below ask whether BPC-157 or Thymosin Beta-4 has enough safety study. They found too little human work to judge the blend. No paper below tested BPC-157 TB-500 together. The study findings explain what the animal work did show.
The animal papers answer narrower questions. Some tested rat tendons, skin wounds, muscles, or blood flow. Some used the whole protein, while TB-500 was the shorter substance. A finding applies only to the animal and substance named.
The FDA pages answer approval and pharmacy questions. They show the listing requests as withdrawn and neither part as approved. The federal pharmacy page gives the practical effect. None of these sources supplies a human blend dose for you.
- Staresinic M, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. ↗
- Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95:323-333. ↗
- Irobi E, et al. Structural basis of actin sequestration by thymosin-beta4: implications for WH2 proteins. EMBO J. 2004. ↗
- Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin beta4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012. ↗
- Malinda KM, et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999. ↗
- Philp D, et al. Thymosin beta4 increases hair growth by activation of hair follicle stem cells. FASEB J. 2004. ↗
- Philp D, et al. Thymosin beta4 promotes angiogenesis, wound healing, and hair follicle development. Mech Ageing Dev. 2004. ↗
- Esposito S, et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012. ↗
- Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025. ↗
- Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026. ↗
- Protective Effects of BPC 157 on Liver, Kidney, and Lung Distant Organ Damage in Rats with Experimental Lower-Extremity Ischemia-Reperfusion Injury. Medicina (Kaunas). 2025;61(2):291. ↗
- U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks (Category 2; BPC-157 and "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500" entries effective with the September 29, 2023 update); and Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. ↗
- U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee (agenda lists BPC-157 and TB-500 as bulk drug substances being considered for inclusion on the 503A Bulks List). ↗
- Cha HJ, Jeong MJ, Kleinman HK. Role of thymosin beta4 in tumor metastasis and angiogenesis. J Natl Cancer Inst. 2003. ↗
- et al. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025. ↗
- Ho ENM, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin beta4, in equine urine and plasma by liquid chromatography-mass spectrometry. J Chromatogr A. 2012. ↗
- Ruff D, et al. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. Ann N Y Acad Sci. 2010. ↗
- et al. A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin beta4 in healthy Chinese volunteers. J Cell Mol Med. 2021. ↗